-
Je něco špatně v tomto záznamu ?
Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers
M. Vocka, M. Zimovjanova, Z. Bielcikova, P. Tesarova, L. Petruzelka, M. Mateju, L. Krizova, J. Kotlas, J. Soukupova, M. Janatova, P. Zemankova, P. Kleiblova, J. Novotny, B. Konopasek, M. Chodacka, M. Brychta, M. Sochor, D. Smejkalova-Musilova, V....
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
NV15-28830A
MZ0
CEP - Centrální evidence projektů
PROGRES Q28/LF1
Univerzita Karlova v Praze
SVV2018/260367
Univerzita Karlova v Praze
Digitální knihovna NLK
Plný text - Článek
Zdroj
NLK
Free Medical Journals
od 2009
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
PubMed
31141992
DOI
10.3390/cancers11060738
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Breast cancer (BC) prognosis in BRCA1 and BRCA2 mutation carriers has been reported contradictorily, and the significance of variables influencing prognosis in sporadic BC is not established in BC patients with hereditary BRCA1/BRCA2 mutations. In this retrospective cohort study, we analyzed the effect of clinicopathological characteristics on BC prognosis (disease-free survival [DFS] and disease-specific survival [DSS]) in hereditary BRCA1/BRCA2 mutation carriers. We enrolled 234 BRCA1/BRCA2 mutation carriers and 899 non-carriers, of whom 191 carriers and 680 non-carriers, with complete data, were available for survival analyses. We found that patients with ER-positive tumors developed disease recurrence 2.3-times more likely when they carried a BRCA1/BRCA2 mutation (23/60; 38.3% ER-positive carriers vs. 74/445; 16.6% ER-positive non-carriers; p < 0.001). ER-positive mutation carriers also had a 3.4-times higher risk of death due to BC compared with ER-positive non-carriers (13/60; 21.7% vs. 28/445; 6.3%; p < 0.001). Moreover, prognosis in ER-negative BRCA1/BRCA2 mutation carriers was comparable with that in ER-positive non-carriers. Our study demonstrates that ER-positivity worsens BC prognosis in BRCA1/BRCA2 mutation carriers, while prognosis for carriers with ER-negative tumors (including early-onset) is significantly better and comparable with that in ER-positive, older BC non-carriers. These observations indicate that BRCA1/BRCA2 mutation carriers with ER-positive BC represent high-risk patients.
Department of Oncology Chomutov Hospital Kochova 1185 430 01 Chomutov Czech Republic
Department of Oncology Masaryk Hospital Socialni pece 3316 12 401 13 Usti nad Labem Czech Republic
Department of Oncology Medicon Roskotova 1717 2 140 00 Prague 4 Czech Republic
Department of Oncology Vzdusna 1360 6 460 01 Liberec Czech Republic
Department of Surgery Sunderby Hospital Sjukhusvägen 10 954 42 Sunderbyn Sweden
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028955
- 003
- CZ-PrNML
- 005
- 20220509175557.0
- 007
- ta
- 008
- 190813s2019 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cancers11060738 $2 doi
- 035 __
- $a (PubMed)31141992
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Vocka, Michal $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital, U Nemocnice 499/2, 128 00 Prague 2, Czech Republic. michal.vocka@vfn.cz.
- 245 10
- $a Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers / $c M. Vocka, M. Zimovjanova, Z. Bielcikova, P. Tesarova, L. Petruzelka, M. Mateju, L. Krizova, J. Kotlas, J. Soukupova, M. Janatova, P. Zemankova, P. Kleiblova, J. Novotny, B. Konopasek, M. Chodacka, M. Brychta, M. Sochor, D. Smejkalova-Musilova, V. Cmejlova, R. Kozevnikovova, L. Miskarova, S. Argalacsova, L. Stolarova, K. Lhotova, M. Borecka, Z. Kleibl,
- 520 9_
- $a Breast cancer (BC) prognosis in BRCA1 and BRCA2 mutation carriers has been reported contradictorily, and the significance of variables influencing prognosis in sporadic BC is not established in BC patients with hereditary BRCA1/BRCA2 mutations. In this retrospective cohort study, we analyzed the effect of clinicopathological characteristics on BC prognosis (disease-free survival [DFS] and disease-specific survival [DSS]) in hereditary BRCA1/BRCA2 mutation carriers. We enrolled 234 BRCA1/BRCA2 mutation carriers and 899 non-carriers, of whom 191 carriers and 680 non-carriers, with complete data, were available for survival analyses. We found that patients with ER-positive tumors developed disease recurrence 2.3-times more likely when they carried a BRCA1/BRCA2 mutation (23/60; 38.3% ER-positive carriers vs. 74/445; 16.6% ER-positive non-carriers; p < 0.001). ER-positive mutation carriers also had a 3.4-times higher risk of death due to BC compared with ER-positive non-carriers (13/60; 21.7% vs. 28/445; 6.3%; p < 0.001). Moreover, prognosis in ER-negative BRCA1/BRCA2 mutation carriers was comparable with that in ER-positive non-carriers. Our study demonstrates that ER-positivity worsens BC prognosis in BRCA1/BRCA2 mutation carriers, while prognosis for carriers with ER-negative tumors (including early-onset) is significantly better and comparable with that in ER-positive, older BC non-carriers. These observations indicate that BRCA1/BRCA2 mutation carriers with ER-positive BC represent high-risk patients.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Zimovjanova, Martina $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital, U Nemocnice 499/2, 128 00 Prague 2, Czech Republic. martina.zimovjanova@vfn.cz.
- 700 1_
- $a Bielcikova, Zuzana $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital, U Nemocnice 499/2, 128 00 Prague 2, Czech Republic. zuzana.bielcikova@vfn.cz.
- 700 1_
- $a Tesarova, Petra $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital, U Nemocnice 499/2, 128 00 Prague 2, Czech Republic. petra.tesarova@vfn.cz.
- 700 1_
- $a Petruzelka, Lubos $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital, U Nemocnice 499/2, 128 00 Prague 2, Czech Republic. lubos.petruzelka@vfn.cz.
- 700 1_
- $a Mateju, Martin $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital, U Nemocnice 499/2, 128 00 Prague 2, Czech Republic. martin.mateju@vfn.cz.
- 700 1_
- $a Krizova, Ludmila $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital, U Nemocnice 499/2, 128 00 Prague 2, Czech Republic. ludmila.krizova@vfn.cz.
- 700 1_
- $a Kotlas, Jaroslav $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital, Albertov 4, 128 00 Prague 2, Czech Republic. jaroslav.kotlas@vfn.cz.
- 700 1_
- $a Soukupova, Jana $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 00 Prague 2, Czech Republic. jana.soukupova@lf1.cuni.cz.
- 700 1_
- $a Janatova, Marketa $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 00 Prague 2, Czech Republic. marketa.janatova@lf1.cuni.cz.
- 700 1_
- $a Zemankova, Petra $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 00 Prague 2, Czech Republic. petra.zemankova@lf1.cuni.cz.
- 700 1_
- $a Kleiblova, Petra $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital, Albertov 4, 128 00 Prague 2, Czech Republic. pekleje@lf1.cuni.cz. Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 00 Prague 2, Czech Republic. pekleje@lf1.cuni.cz.
- 700 1_
- $a Novotny, Jan $u Department of Surgery, Sunderby Hospital, Sjukhusvägen 10, 954 42 Sunderbyn, Sweden. onkologie@seznam.cz.
- 700 1_
- $a Konopasek, Bohuslav $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital, U Nemocnice 499/2, 128 00 Prague 2, Czech Republic. bohuslav.konopasek@vfn.cz.
- 700 1_
- $a Chodacka, Martina $u Department of Oncology, Chomutov Hospital, Kochova 1185, 430 01 Chomutov, Czech Republic. martina.chodacka@kzcr.eu.
- 700 1_
- $a Brychta, Milan $u Department of Radiotherapy and Oncology, Third Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady, Srobarova 1150/50, 100 34 Prague 10, Czech Republic. brychta@fnkv.cz.
- 700 1_
- $a Sochor, Marek $u Department of Oncology, Vzdusna 1360/6, 460 01 Liberec, Czech Republic. sochor.marek73@gmail.com.
- 700 1_
- $a Smejkalova-Musilova, Denisa $u Department of Oncology, Masaryk Hospital, Socialni pece 3316/12, 401 13 Usti nad Labem, Czech Republic. denisa.smejkalovamusilova@kzcr.eu.
- 700 1_
- $a Cmejlova, Vlastimila $u Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, 150 06 Prague 5, Czech Republic. v.cmejlova@seznam.cz.
- 700 1_
- $a Kozevnikovova, Renata $u Department of Oncology, Medicon, Roskotova 1717/2, 140 00 Prague 4, Czech Republic. r.kozevnikovova@email.cz.
- 700 1_
- $a Miskarova, Lenka $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Videnska 800, 140 59 Prague 4, Czech Republic. lenka.mockova@gmail.com.
- 700 1_
- $a Argalacsova, Sona $u Institute of Radiation Oncology, First Faculty of Medicine, Charles University and Hospital Na Bulovce, Budinova 2, 180 00 Prague 8, Czech Republic. argi@centrum.cz.
- 700 1_
- $a Stolarova, Lenka $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 00 Prague 2, Czech Republic. lenka.stolarova@lf1.cuni.cz.
- 700 1_
- $a Lhotova, Klara $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 00 Prague 2, Czech Republic. klara.lhotova@lf1.cuni.cz.
- 700 1_
- $a Borecka, Marianna $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 00 Prague 2, Czech Republic. marianna.borecka@lf1.cuni.cz.
- 700 1_
- $a Kleibl, Zdenek $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 00 Prague 2, Czech Republic. zdekleje@lf1.cuni.cz.
- 773 0_
- $w MED00173178 $t Cancers $x 2072-6694 $g Roč. 11, č. 6 (2019)
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20220509175555 $b ABA008
- 999 __
- $a ind $b bmc $g 1434104 $s 1067415
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 11 $c 6 $e 20190528 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
- GRA __
- $a NV15-28830A $p MZ0
- GRA __
- $a PROGRES Q28/LF1 $p Univerzita Karlova v Praze
- GRA __
- $a SVV2018/260367 $p Univerzita Karlova v Praze
- LZP __
- $a Pubmed-20190813
